Sectors
Share
The most vulnerable US citizens are those who could feel the biggest impact from incoming pharma tariffs
Our take on why ESG in healthcare is here to stay
Trump's tariff threat on the pharmaceutical industry
2025 promises to be a tumultuous year for the American healthcare and pharma industry
By Diederik Stadig